IL89701A - Recombinant retroviruses method for the production thereof and pharmaceutical compositions containing the same - Google Patents
Recombinant retroviruses method for the production thereof and pharmaceutical compositions containing the sameInfo
- Publication number
- IL89701A IL89701A IL8970189A IL8970189A IL89701A IL 89701 A IL89701 A IL 89701A IL 8970189 A IL8970189 A IL 8970189A IL 8970189 A IL8970189 A IL 8970189A IL 89701 A IL89701 A IL 89701A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- expression
- recombinant retrovirus
- retrovirus
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17051588A | 1988-03-21 | 1988-03-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL89701A0 IL89701A0 (en) | 1989-09-28 |
IL89701A true IL89701A (en) | 1995-07-31 |
Family
ID=22620165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL8970189A IL89701A (en) | 1988-03-21 | 1989-03-21 | Recombinant retroviruses method for the production thereof and pharmaceutical compositions containing the same |
Country Status (16)
Country | Link |
---|---|
EP (2) | EP0702084B1 (ja) |
JP (5) | JPH03504079A (ja) |
CN (1) | CN1038306A (ja) |
AT (2) | ATE187983T1 (ja) |
AU (1) | AU651311B2 (ja) |
CA (1) | CA1341585C (ja) |
CH (1) | CH684094A5 (ja) |
DE (2) | DE68929122T2 (ja) |
DK (1) | DK175857B1 (ja) |
ES (1) | ES2139810T3 (ja) |
FI (1) | FI113476B (ja) |
GB (2) | GB2236753B (ja) |
GR (1) | GR3032940T3 (ja) |
IL (1) | IL89701A (ja) |
NO (1) | NO314596B1 (ja) |
WO (1) | WO1989009271A1 (ja) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5997859A (en) * | 1988-03-21 | 1999-12-07 | Chiron Corporation | Method for treating a metastatic carcinoma using a conditionally lethal gene |
US5591624A (en) * | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
US6133029A (en) | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US5662896A (en) * | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
US6569679B1 (en) | 1988-03-21 | 2003-05-27 | Chiron Corporation | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene |
US5614404A (en) * | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
US5747324A (en) * | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
US5650148A (en) * | 1988-12-15 | 1997-07-22 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
EP0454781B1 (en) * | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
DE69033975T2 (de) * | 1989-01-23 | 2002-10-02 | Chiron Corp | Rekombinanttherapien für Infektionen und hyperproliferative Störungen |
JP3140757B2 (ja) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥hivプロウイルス、細胞系及びその使用 |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
EP0466815A4 (en) * | 1989-04-05 | 1992-09-02 | Novacell Corpporation | Infectious targetted replication-defective virion |
WO1991002805A2 (en) * | 1989-08-18 | 1991-03-07 | Viagene, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
US6337209B1 (en) | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
DE69033710T2 (de) * | 1989-10-24 | 2001-06-13 | Chiron Corp | Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein |
FR2655855B1 (fr) * | 1989-12-20 | 1992-04-10 | Pasteur Institut | Protection genetique d'animaux contre l'infection par le virus leucemogene bovin, et provirus et virus recombinant derive de ce virus. |
US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
US6555108B1 (en) * | 1990-09-14 | 2003-04-29 | The General Hospital Corporation | Implanting HSV-TK retrovirus producing cells to treat tumors |
US6537541B1 (en) * | 1990-09-14 | 2003-03-25 | The General Hospital Corporation | Implantation of HSV-TK retrovirus producer cells to destroy glioma |
JPH06500923A (ja) * | 1990-09-21 | 1994-01-27 | カイロン コーポレイション | パッケージング細胞 |
WO1992005263A1 (en) * | 1990-09-25 | 1992-04-02 | Cantab Pharmaceuticals Research Limited | Viral defective vaccine produced by transcomplementing cell line |
US7374768B1 (en) | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
US5665362A (en) * | 1990-09-25 | 1997-09-09 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
US5837261A (en) * | 1990-09-25 | 1998-11-17 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
GB9100612D0 (en) * | 1991-01-11 | 1991-02-27 | Univ Edinburgh | Method of altering the metabolic state of non-dividing cells,transgenic animals and therapeutic agents |
GB9104165D0 (en) * | 1991-02-27 | 1991-04-17 | Wellcome Found | Novel entities for hiv therapy |
GB9107631D0 (en) * | 1991-04-10 | 1991-05-29 | British Bio Technology | Proteinaceous particles |
WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
WO1993005147A1 (en) * | 1991-08-30 | 1993-03-18 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Defective interfering hiv particles with chimeric cd4-env |
ATE188124T1 (de) * | 1991-10-30 | 2000-01-15 | Univ Paris Curie | Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB2269175A (en) * | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
US7223411B1 (en) | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
ATE263252T1 (de) * | 1992-11-09 | 2004-04-15 | Us Health | Erzielbare vektorenpartikel |
WO1994016072A1 (en) * | 1993-01-14 | 1994-07-21 | Intracell Therapeutics, Inc. | Vectors useful for controlling hiv-1 replication and methods for using the same |
KR960703172A (ko) | 1993-11-18 | 1996-06-19 | 스티븐 제이. 멘토 | 조건적으로 치사적인 유전자를 활용하기 위한 조성물 및 방법(Compositions and methods for utilizing conditionally lethal genes) |
DE69524740T2 (de) * | 1994-05-02 | 2002-08-14 | Univ Washington Seattle | Thymidin-kinase-mutanten |
US6451571B1 (en) | 1994-05-02 | 2002-09-17 | University Of Washington | Thymidine kinase mutants |
US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
AU2648295A (en) * | 1994-06-07 | 1996-01-04 | Immunomedics Inc. | Safe retroviral vectors, their production and use |
GB9414652D0 (en) * | 1994-07-20 | 1994-09-07 | Moeller Erna | Method of treatment |
WO1997015679A1 (en) * | 1995-10-27 | 1997-05-01 | The Trustees Of The University Of Pennsylvania | Recombinant viruses containing mobile genetic elements and methods of use in gene therapy |
FR2741358B1 (fr) * | 1995-11-17 | 1998-01-02 | Centre Nat Rech Scient | Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn |
US6365344B1 (en) | 1996-01-23 | 2002-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
EP0877752B1 (en) | 1996-01-23 | 2003-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and rna molecules |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
WO1998003669A2 (en) * | 1996-07-22 | 1998-01-29 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vectors for inhibiting hiv and tumor growth |
US6953687B1 (en) | 1997-07-17 | 2005-10-11 | The United States Of America As Represented By The Department Of Health And Human Services | Vectors for delivering viral and oncogenic inhibitors |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
GB9703802D0 (en) | 1997-02-24 | 1997-04-16 | Kingsman Susan M | Anti-hiv peptides and proteins |
IL132087A0 (en) | 1997-04-10 | 2001-03-19 | Univ Southern California | Modified proteins which bind extracellular matrix components |
GB9711578D0 (en) * | 1997-06-04 | 1997-07-30 | Oxford Biomedica Ltd | Novel retroviral vector production systems |
DE19737442C2 (de) * | 1997-08-22 | 1999-06-24 | Olfert Landt Tib Molbiol Synth | Proteinumhüllte Polyribonukleinsäuren, ein Verfahren zu ihrer Herstellung und ihre Verwendung |
EP1009444A2 (en) * | 1997-09-02 | 2000-06-21 | Chiron Corporation | Compositions and methods for treating arthritis utilizing gene therapy |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
EP1900818A3 (en) | 1997-11-06 | 2008-06-11 | Novartis Vaccines and Diagnostics S.r.l. | Neisserial antigens |
JP4399112B2 (ja) | 1998-01-14 | 2010-01-13 | カイロン ソチエタ ア レスポンサビリタ リミタータ | NeisseriaMeningitidis抗原 |
US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
US7576176B1 (en) | 1998-05-01 | 2009-08-18 | Novartis Vaccines And Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
AU5323599A (en) * | 1998-07-29 | 2000-02-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Use of constitutive transport elements for host range control |
US6399354B1 (en) | 1998-07-31 | 2002-06-04 | President And Fellows Of Harvard College | Replication-competent virus expressing a detectable fusion protein |
WO2000039302A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
CN100392082C (zh) | 1999-04-30 | 2008-06-04 | 启龙股份公司 | 保守的奈瑟球菌抗原 |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
PT1092779E (pt) * | 1999-10-11 | 2010-01-19 | Pasteur Institut | Vectores lentivíricos para a preparação de composições imunoterapêuticas |
EP2275553B1 (en) | 1999-10-29 | 2015-05-13 | Novartis Vaccines and Diagnostics S.r.l. | Neisserial antigenic peptides |
EP1897555B1 (en) | 2000-01-17 | 2014-07-16 | Novartis Vaccines and Diagnostics S.r.l. | Supplemented OMV vaccine against meningococcus |
DE60126249T2 (de) | 2000-02-28 | 2008-05-29 | Novartis Vaccines And Diagnostics S.R.L. | Heterologe expression von neisseria-proteinen |
NZ583028A (en) | 2000-10-27 | 2011-10-28 | Novartis Vaccines & Diagnostic | Nucleic acids and proteins from streptococcus groups A & B |
US6713055B2 (en) | 2000-11-27 | 2004-03-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
AU2002236517A1 (en) | 2000-11-29 | 2002-06-11 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
FR2820146B1 (fr) * | 2001-01-29 | 2003-06-27 | Centre Nat Rech Scient | Procede d'obtention de cellules d'encapsidation fortement productrices de retrovirus par elimination, au sein de la culture, des cellules permissives a l'infection par le retro virus produit |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0111442D0 (en) * | 2001-05-10 | 2001-07-04 | Isis Innovation | Method for preparing recombinant virus |
JP5033303B2 (ja) | 2001-07-05 | 2012-09-26 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 抗原性c型hivポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用 |
EP1409694A4 (en) | 2001-07-05 | 2006-02-08 | Chiron Corp | POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF |
EP1463520B1 (en) | 2001-12-12 | 2008-09-03 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia trachomatis |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
EP1619951B1 (en) | 2003-04-21 | 2011-06-22 | Epeius Biotechnologies Corporation | Methods and compositions for treating disorders |
DK1736541T3 (da) | 2004-03-29 | 2013-05-06 | Galpharma Co Ltd | Nyt modificeret galectin 9-protein og anvendelse heraf |
GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
CN107022217A (zh) * | 2017-06-08 | 2017-08-08 | 南通市乐佳涂料有限公司 | 一种采用水包水的环保抗锈涂料 |
CN109722465B (zh) * | 2019-01-07 | 2022-02-01 | 福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) | 一种hiv耐药检测载体和构建方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2559159B1 (fr) * | 1984-02-02 | 1986-09-12 | Inst Nat Sante Rech Med | Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues |
CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
FR2606030B1 (fr) * | 1986-10-31 | 1989-10-20 | Pasteur Institut | Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci |
AU647013B2 (en) * | 1988-08-22 | 1994-03-17 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Retroviral vectors expressing soluble CD4: a gene therapy for aids |
-
1989
- 1989-03-20 AU AU33640/89A patent/AU651311B2/en not_active Expired
- 1989-03-20 CN CN89102697A patent/CN1038306A/zh active Granted
- 1989-03-20 JP JP1503903A patent/JPH03504079A/ja not_active Withdrawn
- 1989-03-20 WO PCT/US1989/001139 patent/WO1989009271A1/en active IP Right Grant
- 1989-03-20 CH CH4290/89A patent/CH684094A5/de not_active IP Right Cessation
- 1989-03-21 CA CA005943744A patent/CA1341585C/en not_active Expired - Fee Related
- 1989-03-21 IL IL8970189A patent/IL89701A/en unknown
- 1989-03-21 AT AT95115441T patent/ATE187983T1/de not_active IP Right Cessation
- 1989-03-21 EP EP95115441A patent/EP0702084B1/en not_active Revoked
- 1989-03-21 AT AT89105059T patent/ATE174960T1/de not_active IP Right Cessation
- 1989-03-21 ES ES95115441T patent/ES2139810T3/es not_active Expired - Lifetime
- 1989-03-21 DE DE68929122T patent/DE68929122T2/de not_active Revoked
- 1989-03-21 DE DE68928884T patent/DE68928884T2/de not_active Expired - Fee Related
- 1989-03-21 EP EP89105059A patent/EP0334301B1/en not_active Expired - Lifetime
-
1990
- 1990-09-20 GB GB9020586A patent/GB2236753B/en not_active Expired - Lifetime
- 1990-09-20 FI FI904647A patent/FI113476B/fi not_active IP Right Cessation
- 1990-09-20 DK DK199002268A patent/DK175857B1/da not_active IP Right Cessation
- 1990-09-20 NO NO19904103A patent/NO314596B1/no not_active IP Right Cessation
-
1992
- 1992-08-10 GB GB9217086A patent/GB2255777B/en not_active Expired - Fee Related
-
1998
- 1998-12-24 JP JP10368260A patent/JPH11262397A/ja not_active Withdrawn
-
2000
- 2000-03-10 GR GR20000400636T patent/GR3032940T3/el not_active IP Right Cessation
-
2002
- 2002-03-11 JP JP2002066181A patent/JP2002306188A/ja not_active Withdrawn
-
2003
- 2003-10-10 JP JP2003353011A patent/JP2004008227A/ja active Pending
-
2007
- 2007-08-01 JP JP2007200751A patent/JP2007289206A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1341585C (en) | Recombinant retroviruses | |
US6495349B1 (en) | Chimeric gene constructs | |
CA2066053C (en) | Recombinant retroviruses delivering vector constructs to target cells | |
US5856185A (en) | Method for making reflection defective retroviral vectors for infecting human cells | |
US5997859A (en) | Method for treating a metastatic carcinoma using a conditionally lethal gene | |
CA2158936C (en) | Compositions and methods for utilizing conditionally lethal genes | |
JPH11505128A (ja) | キメラインテグラーゼタンパク質に媒介される真核生物ゲノム中へのベクター構築物の位置特異的組み込み | |
AU689799B2 (en) | Recombinant retroviruses | |
US6569679B1 (en) | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene | |
GB2254424A (en) | Indicator cells and retroviruses for the detection of gene sequenes | |
US20060121011A1 (en) | Combination gene delivery vehicles | |
Li | Use of retroviral vectors in studying gag-specific CTL in cats infected with feline immunodeficiency virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed |